Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)

Clinical trial NCT02736656 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT02736656
Sponsor: Supernus Pharmaceuticals, Inc.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Attention-Deficit/Hyperactivity Disorder

Start date: 2016-02-02
Primary completion: 2026-09-01
Enrollment: 1400

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.